血液乙肝病毒大蛋白含量与乙肝抗病毒治疗疗效的相关性研究

CORRELATION OF HEPATITIS B VIRUS LARGE PROTEIN LEVEL IN BLOOD AND EFFICACY OF ANTIVIRAL THERAPY TO TYPE B HEPATITIS

目的:探讨乙型肝炎病毒表面大蛋白含量用于临床治疗的价值以及与乙肝病毒DNA的相关性。方法:选择我院200例抗病毒治疗的门诊和住院乙肝患者,在用药的0周、12周、24周、36周、48周采集血液标本,分别检测ALT、HBV DNA拷贝数、HBeAg、LHBs。结果:随着HBV DNA拷贝数的升高LHBs的浓度呈上升趋势;同一HBV DNA拷贝数的乙肝患者LHBs和HBeAg的阳性率比较具有显著差异(P<0.01,P<0.05);在不同治疗时期,LHBs转阴率、DNA拷贝数、HBeAg转阴率具有显著差异(P<0.01)。结论:血液中HBV DNA阴转并不意味着肝内乙肝病毒复制的消失,LHBs含量有望作为乙肝抗病毒治疗终点的一个可靠指标。

Objective：To explore the therapeutic value of hepatitis B virus surface large protein level in clinic and its correlation with hepatitis B virus DNA.Methods：200 cases of anti-viral treatment hepatitis B patients were chosen in this study.The blood were collected at 0 week,12 weeks,24 weeks,36 weeks,48 weeks of medication and the ALT,HBV DNA copy number,HBeAg and LHBs in blood were tested respectively.Results：With increasing of HBV DNA copy number,the concentration of LHBs raised.There had obvious differences between HBeAg and LHBs positive rate of patients with equal HBV DNA copy number（P〈0.01,P〈0.05）.At different treating period,the HBV DNA copy number,the LHBs and HBeAg negative conversion rate had significant differences（P0〈.01）.Conclusions：HBV DNA negative conversion in blood does not mean disappearance of intrahepatic hepatitis B virus replication;LHBs content is expected to be a reliable indicator to judge antiviral therapy destination and avoid over-treatment.